NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
复制标题
NCCN 指南见解：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，版本 1.2017。
DOI：
--
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
T. Fioretos
中科院分区：
文献类型：
--
作者：
Carl Sandén;H. Lilljebjörn;Christina Orsmark Pietras;Rasmus Henningsson;K. Saba;N. Landberg;Hanna Thorsson;S. von Palffy;Pablo Peña;Carl Högberg;M. Rissler;D. Gisselsson;V. Lazarevic;G. Juliusson;H. Ågerstam;T. Fioretos
慢性淋巴细胞性白血病(CLL)和小淋巴细胞性淋巴瘤(SLL)是同一疾病的不同表现，其处理方式大致相同。新的CD20单抗的出现导致了有效的化学免疫治疗方案的发展。最近，针对一些关键信号通路的小分子激酶抑制剂和bcl2蛋白家族的小分子抑制剂已经显示出治疗CLL/SLL患者的活性。这些NCCN指南洞察重点介绍了NCCN肿瘤学临床实践指南(NCCN指南)的重要更新，用于治疗新诊断或复发/难治性CLL/SLL患者。
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.